| Literature DB >> 29207677 |
Rui Hou1, Shen-Shen Yao1, Jia Liu1, Lian-Lian Wang1, Lang Wu2, Luo Jiang3.
Abstract
The relationship between intake of fish and n-3 fatty acids and endometrial cancer risk has not been consistent across epidemiological studies. We quantitatively assessed the aforementioned association through a systematic review and meta-analysis. PubMed and Embase were searched through March 2017 for eligible epidemiological studies. Fixed or random-effects models were used to pool relative risks (RRs) and 95% confidence intervals (CIs). The dose-response relationship was also evaluated. Based on the literature search, five prospective studies and 11 case-control studies were identified. All 16 studies were categorized as high-quality studies. After pooling available risk estimates, no significant association was detected between overall fish intake and endometrial cancer risk. In subgroup analyses, every one additional serving/week of fish intake was significantly associated with inversed endometrial cancer risk in studies adjusted for smoking (RR (95% CI): 0.95 (0.91-1.00)), or studies performed in Europe (RR (95% CI): 0.90 (0.84-0.97)), but not in other tested subgroups. In studies conducted in Asia, there was significant positive association (RR (95% CI): 1.15 (1.10-1.21)). Regarding n-3 PUFA intake, marginally inverse associations of high EPA or DHA intake were detected (EPA: RR (95% CI) = 0.79 (0.61-1.04); DHA: RR (95% CI) = 0.85 (0.64-1.11)). Dose-response analyses suggested a significant nonlinear relationship between DHA intake and endometrial cancer risk (p: 0.04). Overall, this meta-analysis suggests that intake of n-3 PUFA may be inversely associated with endometrial cancer risk at some level of evidence, although the exact relationship, especially for fish intake, needs further characterization. Further well-designed studies are warranted.Entities:
Keywords: endometrial cancer; epidemiology; fish; n-3 fatty acids
Year: 2017 PMID: 29207677 PMCID: PMC5710957 DOI: 10.18632/oncotarget.18295
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Figure 1Flow chart for selection of eligible studies
Quality assessment of included prospective studies using the Newcastle-Ottawa Quality assessment scale*
| Study | Exposed cohort represents average in community | Selection of the non-exposed cohort from same community | Ascertain exposure through records or structured interviews | Demonstrate that outcome not present at study start | Exposed and non-exposed matched and/or adjusted by factors | Ascertain outcome via independent blind assessment or record linkage | Follow-up long enough for outcome to occur | Loss to follow-up < 20% | Overall Score |
|---|---|---|---|---|---|---|---|---|---|
| Brasky, 2014 | 1 | 1 | 0 | 1 | 2 | 1 | 1 | 1 | 8 |
| Brasky, 2016 | 1 | 1 | 0 | 1 | 2 | 1 | 1 | 1 | 8 |
| Daniel, 2011 | 1 | 1 | 0 | 1 | 2 | 1 | 1 | 1 | 8 |
| van Lonkhuijzen, 2011 | 1 | 1 | 0 | 1 | 2 | 1 | 1 | 1 | 8 |
| Brasky, 2015 | 1 | 1 | 0 | 1 | 2 | 1 | 1 | 1 | 8 |
*A study could be awarded a maximum of one star for each item except for the item Control for important factor or additional factor. The definition/explanation of each column of the Newcastle-Ottawa Scale is available from (http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.). 1 means study adequately fulfilled a quality criterion (2 for exposed and non-exposed fully matched or adjusted by factors), 0 means it did not. Quality scale does not imply that items are of equal relevant importance
Quality assessment of included case-control studies using the Newcastle-Ottawa Quality assessment scale*
| Study | Case defined with independent validation | Representativeness of the cases | Selection of controls from community | Statement that controls have no history of outcome | Cases and controls matched and/or adjusted by factors | Ascertain exposure by blinded structured interview | Same method of ascertainment for cases and controls | Same response rate for both groups | Overall Score |
|---|---|---|---|---|---|---|---|---|---|
| Arem, 2013 | 0 | 1 | 1 | 1 | 2 | 0 | 1 | 1 | 7 |
| Filomeno, 2015 | 1 | 1 | 0 | 1 | 2 | 1 | 1 | 1 | 8 |
| Hirose, 1996 | 1 | 1 | 0 | 1 | 2 | 0 | 1 | 1 | 7 |
| Takayama, 2013 | 1 | 1 | 1 | 1 | 2 | 0 | 1 | 1 | 8 |
| Terry, 2002 | 1 | 1 | 1 | 0 | 2 | 0 | 1 | 1 | 7 |
| Xu, 2006 | 1 | 1 | 1 | 0 | 2 | 1 | 1 | 1 | 8 |
| McCann, 2000 | 1 | 1 | 1 | 0 | 2 | 1 | 1 | 1 | 8 |
| Jain, 2000 | 1 | 1 | 1 | 0 | 2 | 1 | 1 | 0 | 7 |
| Shu, 1993 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 7 |
| Goodman, 1997 | 1 | 1 | 1 | 0 | 2 | 1 | 1 | 1 | 8 |
| Fernandez, 1999 | 1 | 1 | 0 | 1 | 2 | 1 | 1 | 1 | 8 |
*A study could be awarded a maximum of one star for each item except for the item Control for important factor or additional factor. The definition/explanation of each column of the Newcastle-Ottawa Scale is available from (http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.). 1 means study adequately fulfilled a quality criterion (2 for case-control fully matched and adjusted), 0 means it did not. Quality scale does not imply that items are of equal relevant importance
Summary risk estimates of the association between fish consumption and endometrial cancer risk (the highest category versus the lowest category)
| No. of reports | RR (95% CI) | |||
|---|---|---|---|---|
| 12 | 1.04 (0.84–1.30) | 80.4% | < 0.001 | |
| Prospective | 4 | 1.09 (0.82–1.45) | 45.7% | 0.137 |
| Case-control | 8 | 1.01 (0.74–1.38) | 86.1% | < 0.001 |
| North America | 7 | 0.99 (0.82–1.19) | 35.3% | 0.158 |
| Europe | 2 | 0.92 (0.74–1.13) | 53.5% | 0.142 |
| Asia | 3 | 1.26 (0.50–3.17) | 91.0% | < 0.001 |
| Population-based | 6 | 0.95 (0.60–1.52) | 89.7% | < 0.001 |
| Hospital-based | 2 | 1.07 (0.81–1.41) | 25.2% | 0.248 |
| < 500 | 6 | 0.98 (0.69–1.39) | 55.8% | 0.046 |
| ≥ 500 | 6 | 1.09 (0.81–1.45) | 88.5% | < 0.001 |
| Earlier than 2010 | 5 | 1.20 (0.72–1.99) | 89.3% | < 0.001 |
| 2010– | 7 | 0.95 (0.78–1.15) | 57.3% | 0.029 |
| Yes | 8 | 1.14 (0.88–1.48) | 83.6% | < 0.001 |
| No | 4 | 0.84 (0.61–1.17) | 47.2% | 0.128 |
| Yes | 9 | 1.14 (0.85–1.54) | 81.8% | < 0.001 |
| No | 3 | 0.84 (0.59–1.21) | 78.7% | 0.009 |
| Yes | 9 | 0.98 (0.86–1.13) | 41.2% | 0.092 |
| No | 3 | 1.06 (0.39–2.85) | 92.7% | < 0.001 |
| Yes | 5 | 0.97 (0.78–1.20) | 44.0% | 0.128 |
| No | 7 | 1.06 (0.74–1.53) | 86.8% | < 0.001 |
Figure 2The association between the highest vs. lowest category of fish consumption and endometrial cancer risk
Summary risk estimates of the association between fish consumption and endometrial cancer risk (every one additional serving/week of fish intake)
| No. of reports | RR (95% CI) | |||
|---|---|---|---|---|
| 10 | 1.00 (0.94–1.07) | 81.7% | < 0.001 | |
| Prospective | 2 | 1.00 (0.97–1.02) | 0% | 0.778 |
| Case-control | 8 | 1.01 (0.92–1.10) | 83.9% | < 0.001 |
| North America | 6 | 1.00 (0.95–1.04) | 32.6% | 0.191 |
| Europe | 2 | 0% | 0.941 | |
| Asia | 2 | 0% | 0.531 | |
| Population-based | 9 | 1.02 (0.93–1.12) | 83.2% | < 0.001 |
| Hospital-based | 1 | 0.90 (0.80–1.00) | - | - |
| < 500 | 5 | 1.03 (0.97–1.10) | 42.5% | 0.138 |
| ≥ 500 | 5 | 0.97 (0.86–1.10) | 90.1% | < 0.001 |
| Earlier than 2010 | 7 | 1.02 (0.93–1.12) | 82.7% | < 0.001 |
| 2010– | 3 | 0.98 (0.94–1.03) | 19.7% | 0.288 |
| Yes | 5 | 1.01 (0.93–1.11) | 88.2% | < 0.001 |
| No | 5 | 0.99 (0.89–1.10) | 72.5% | 0.006 |
| Yes | 6 | 1.01 (0.93–1.09) | 85.4% | <0.001 |
| No | 4 | 1.00 (0.89–1.12) | 79.1% | 0.002 |
| Yes | 6 | 41.1% | 0.131 | |
| No | 4 | 0% | 0.399 | |
| Yes | 3 | 0.98 (0.95–1.02) | 19.5% | 0.289 |
| No | 7 | 1.02 (0.92–1.12) | 82.1% | < 0.001 |
Figure 3Dose-response relationship for the association between intake of DHA and endometrial cancer risk
The solid line represents the estimated relationship. The dashed line represents the 95% confidence interval of the estimated relationship.